BR0010655A - Compostos heterocìclicos para ligação ao receptor de quimiocina - Google Patents

Compostos heterocìclicos para ligação ao receptor de quimiocina

Info

Publication number
BR0010655A
BR0010655A BR0010655-0A BR0010655A BR0010655A BR 0010655 A BR0010655 A BR 0010655A BR 0010655 A BR0010655 A BR 0010655A BR 0010655 A BR0010655 A BR 0010655A
Authority
BR
Brazil
Prior art keywords
group
optionally substituted
ring
binding
compounds
Prior art date
Application number
BR0010655-0A
Other languages
English (en)
Inventor
Gary Bridger
Renato Skerlj
Al Kaller
Curtis Harwig
David Bogucki
Trevor R Wilson
Jason Crawford
Ernest J Mceachern
Bern Atsma
Siqiao Nan
Yuanxi Zhou
Dominique Schols
Original Assignee
Anormed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anormed Inc filed Critical Anormed Inc
Publication of BR0010655A publication Critical patent/BR0010655A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Patente da Invenção: "COMPOSTOS HETEROCìCLICOS PARA LIGAçãO AO RECEPTOR DE QUIMIOCINA". A presente invenção se refere a uma nova classe de compostos heterocíclicos que se ligam a receptores de quimiocina inibindo a ligação de seus ligantes naturais aos mesmos. Esses compostos resultam em efeitos protetores contra infecção pelo HIV através de ligação aos receptores de quimiocina, incluindo CXCR4 e CCR5, assim, inibindo a subseq³ente ligação por essas quimiocinas. A presente invenção proporciona um composto da fórmula (I) em que W é um átomo de nitrogênio e Y está ausente ou W é um átomo de carbono e Y= H; R^ 1^ a R^ 7^ podem ser os mesmos ou diferentes e são, indepentemente, selecionados de hidrogênio ou C~ 1-6~ alquila cíclica reta ou ramificada; R^ 8^ é um grupo heterocíclico substituído ou um grupo aromático substituído; Ar é um anel aromático, cada um opcionalmente substituído em posições únicas ou múltiplas de não ligação com grupos doadores ou extração de elétrons; n e n' são, independentemente, 0-2; X é um grupo da fórmula (a) ou (b) em o Anel A é um anel de 5 ou 6 elementos saturado ou insaturado opcionalmente substituído e P é um átomo de carbono opcionalmente substituído, um átomo de nitrogênio opcionalmente substituído, um átomo de enxofre ou oxigênio. O Anel B é um anel de 5 a 7 elementos opcionalmente substituído. O Anel A e o Anel B na fórmula acima podem ser conectados ao grupo W a partir de qualquer posição via o grupo V, em que V é uma ligação química, um grupo (CH~ 2~)~ n"~ (onde n" = 0-2) ou um grupo C=O. Z é (1) um átomo de hidrogênio, (2) um grupo C~ 1-6~ alquila opcionalmente substituído, (3) um grupo C~ 0-6~ alquila substituído por um grupo aromático heterocíclico opcionalmente substituído, (4) um grupo aromático ou heterocíclico opcionalmente substituído, (4) um grupo C~ 0-4 alquilamino ou C~ 3-7~ cicloalquilamino opcionalmente substituído, (5) um grupo carbonila opcionalmente substituído ou sulfonila. Esses compostos ainda incluem quaisquer sais de adição de ácido farmaceuticamente aceitáveis e complexos de metal dos mesmos e quaisquer formas estereoi-soméricas e misturas de formas estereoisoméricas dos mesmos.
BR0010655-0A 1999-03-24 2000-03-24 Compostos heterocìclicos para ligação ao receptor de quimiocina BR0010655A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12582399P 1999-03-24 1999-03-24
PCT/CA2000/000321 WO2000056729A1 (en) 1999-03-24 2000-03-24 Chemokine recpetor binding heterocyclic compounds

Publications (1)

Publication Number Publication Date
BR0010655A true BR0010655A (pt) 2002-02-13

Family

ID=22421586

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0010655-0A BR0010655A (pt) 1999-03-24 2000-03-24 Compostos heterocìclicos para ligação ao receptor de quimiocina

Country Status (22)

Country Link
US (2) US7629337B2 (pt)
EP (1) EP1163238B1 (pt)
JP (1) JP2003524620A (pt)
KR (1) KR100766289B1 (pt)
CN (1) CN1219780C (pt)
AP (1) AP1654A (pt)
AT (1) ATE327988T1 (pt)
AU (1) AU775123B2 (pt)
BR (1) BR0010655A (pt)
CA (1) CA2368047A1 (pt)
CZ (1) CZ20013421A3 (pt)
DE (1) DE60028354T2 (pt)
ES (1) ES2265923T3 (pt)
HK (1) HK1043985B (pt)
HU (1) HUP0200761A3 (pt)
IL (2) IL145401A0 (pt)
MX (1) MXPA01009674A (pt)
NO (1) NO323703B1 (pt)
NZ (1) NZ514709A (pt)
PL (1) PL350998A1 (pt)
TR (1) TR200102799T2 (pt)
WO (1) WO2000056729A1 (pt)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000046203A2 (en) * 1999-02-04 2000-08-10 Millennium Pharmaceuticals, Inc. G-protein coupled heptahelical receptor binding compounds and methods of use thereof
BR0010655A (pt) * 1999-03-24 2002-02-13 Anormed Inc Compostos heterocìclicos para ligação ao receptor de quimiocina
DE19939980A1 (de) * 1999-08-24 2001-03-01 Merck Patent Gmbh Inhibitoren des Integrins alphavbeta¶3¶
AU2000276225B2 (en) * 1999-09-28 2008-07-10 Neurogen Corporation High affinity small molecule C5A receptor modulators
US6835731B2 (en) * 2000-09-15 2004-12-28 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
PT1317451E (pt) 2000-09-15 2006-12-29 Anormed Inc Compostos heterocíclicos que se ligam a receptores de quimioquinas
CA2419224A1 (en) 2000-09-15 2002-03-21 Anormed Inc. Chemokine receptor binding heterocyclic compounds
EP1322309B1 (en) * 2000-09-29 2008-08-13 Neurogen Corporation High affinity small molecule c5a receptor modulators
CA2429426A1 (en) * 2000-11-17 2002-05-23 Takeda Chemical Industries, Ltd. Isoxazole derivatives
ES2380009T3 (es) * 2001-07-31 2012-05-07 Genzyme Global S.A.R.L. Métodos para movilizar las células madre/progenitoras
US7169750B2 (en) 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
WO2003022785A2 (en) * 2001-09-12 2003-03-20 Anormed Inc. Synthesis of enantiomerically pure amino-substituted fused bicyclic rings
CA2467718C (en) * 2001-12-21 2011-04-26 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US7354932B2 (en) 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
AU2003249983A1 (en) * 2002-07-18 2004-02-09 Actelion Pharmaceuticals Ltd Piperidines useful for the treatment of central nervous system disorders
WO2004018460A1 (en) * 2002-08-21 2004-03-04 Neurogen Corporation Amino methyl imidazoles as c5a receptor modulators
CN100528846C (zh) * 2002-09-11 2009-08-19 株式会社吴羽 胺化合物及其用途
WO2004052862A1 (ja) * 2002-12-10 2004-06-24 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびその医薬用途
WO2004080966A1 (ja) 2003-03-14 2004-09-23 Ono Pharmaceutical Co., Ltd. 含窒素複素環誘導体およびそれらを有効成分とする薬剤
US7504422B2 (en) 2003-04-02 2009-03-17 Taigen Biotechnology Co. Ltd. Polyamine compounds
EP1608352B1 (en) 2003-04-02 2009-12-30 Taigen Biotechnology Polyamine compounds for treating chemokine receptor mediated diseases
EP1613613B1 (en) 2003-04-11 2021-06-02 Genzyme Corporation Cxcr4 chemokine receptor binding compounds
US7498323B2 (en) 2003-04-18 2009-03-03 Ono Pharmaceuticals Co., Ltd. Spiro-piperidine compounds and medicinal use thereof
US7501518B2 (en) 2003-04-22 2009-03-10 Genzyme Corporation Methods of making 2,6-diaryl piperidine derivatives
AU2004232361A1 (en) 2003-04-22 2004-11-04 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
WO2005028467A1 (en) 2003-09-15 2005-03-31 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds
EP1708703A4 (en) 2003-12-11 2008-04-09 Anormed Inc CHEMOKIN RECEPTOR BINDING COMPOUNDS
US7498346B2 (en) 2003-12-11 2009-03-03 Genzyme Corporation Chemokine receptor binding compounds
US7932281B2 (en) 2004-03-10 2011-04-26 Kureha Corporation Amine-based compound and use thereof
CN1930127B (zh) 2004-03-15 2012-11-21 阿诺麦德股份有限公司 用于合成cxcr4拮抗剂的方法
EP1790637B1 (en) 2004-09-13 2014-01-29 Ono Pharmaceutical Co., Ltd. Derivatives of N-4-piperidyl urea and medicaments containing them as active ingredient
ATE474833T1 (de) * 2004-09-22 2010-08-15 Janssen Pharmaceutica Nv Inhibitoren der wechselwirkung zwischen mdm2 und p53
AU2006203826A1 (en) 2005-01-07 2006-07-13 Emory University CXCR4 antagonists for the treatment of HIV infection
WO2006074428A2 (en) * 2005-01-07 2006-07-13 Emory University Cxcr4 antagonists for the treatment of medical disorders
US7501526B2 (en) 2005-01-20 2009-03-10 Taigen Biotechnology Synthesis of polyamine compounds
TW200714610A (en) 2005-02-16 2007-04-16 Univ Maryland CXCR3 is a gliadin receptor
US20110052612A1 (en) 2005-05-31 2011-03-03 Ono Pharmaceutical Co., Ltd. Spiropiperidine compound and medicinal use thereof
EP1942890A4 (en) 2005-06-15 2009-08-26 Genzyme Corp CHEMOKINE RECEPTOR BINDING COMPOUNDS
CA2619828A1 (en) 2005-08-19 2007-02-22 Genzyme Corporation Methods to enhance chemotherapy
PT1942108E (pt) 2005-10-28 2013-10-24 Ono Pharmaceutical Co Composto com um grupo básico e a sua utilização
CN100387595C (zh) * 2005-11-07 2008-05-14 青岛科技大学 一种含苯并三唑的三唑有机化合物、制备方法及应用
WO2007058322A1 (ja) 2005-11-18 2007-05-24 Ono Pharmaceutical Co., Ltd. 塩基性基を含有する化合物およびその用途
WO2007096662A2 (en) 2006-02-27 2007-08-30 Technische Universität München Cancer imaging and treatment
KR20090008217A (ko) 2006-03-10 2009-01-21 오노 야꾸힝 고교 가부시키가이샤 질소 함유 복소환 유도체 및 이들을 유효 성분으로 하는 약제
EP2042503B1 (en) 2006-05-16 2013-01-30 Ono Pharmaceutical Co., Ltd. Compound having acidic group which may be protected, and use thereof
CA2656825C (en) 2006-06-22 2013-12-10 Prana Biotechnology Limited Method of treatment and agents useful for same
EP2041067A4 (en) 2006-07-11 2009-11-25 Univ Emory CXER4 ANTAGONISTS WITH DIAZINE AND TRIAZINE STRUCTURES FOR THE TREATMENT OF MEDICAL PROBLEMS
US7666888B2 (en) 2006-07-20 2010-02-23 Amgen Inc. Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1
WO2008016006A1 (fr) 2006-07-31 2008-02-07 Ono Pharmaceutical Co., Ltd. Composé auquel un groupe cyclique est lié par une liaison spiro et son utilisation
US8350042B2 (en) 2008-01-31 2013-01-08 The Regents Of The University Of California Antiviral compounds for the treatment of HCV infection
AU2009228034A1 (en) 2008-03-28 2009-10-01 Altiris Therapeutics Chemokine receptor modulators
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
KR101831685B1 (ko) * 2010-01-25 2018-02-23 롬 앤드 하스 일렉트로닉 머트어리얼즈 엘엘씨 질소-함유 화합물을 포함하는 포토레지스트
EP2741777B1 (en) 2011-08-12 2017-01-18 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for treatment of pulmonary hypertension
CN107205972A (zh) * 2014-04-23 2017-09-26 X-Rx股份有限公司 自分泌运动因子的取代的n‑(2‑(氨基)‑2‑氧代乙基)苯甲酰胺抑制剂及它们的制备和在治疗lpa‑依赖的或lpa‑介导的疾病中的用途
EP3148537B1 (en) * 2014-05-30 2018-09-26 Université Paris Descartes Cyclic compounds having a 1,3 diamino-functionality for use in the treatment of hiv infection
ES2764840T3 (es) 2015-01-28 2020-06-04 Univ Bordeaux Uso de plerixafor para tratar y/o prevenir exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica
CA3026154A1 (en) 2015-06-03 2016-12-08 The University Of Queensland Mobilizing agents and uses therefor
CN109069426B (zh) 2015-12-14 2021-10-29 X4 制药有限公司 治疗癌症的方法
WO2017106332A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
PL3393468T3 (pl) 2015-12-22 2023-01-23 X4 Pharmaceuticals, Inc. Metody leczenia niedoboru odporności
WO2017160832A1 (en) * 2016-03-14 2017-09-21 Emory University Amide-sulfamide derivatives, compositions, and uses related to cxcr4 inhibition
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
CN109640988A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
WO2017223243A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
ES2870920T3 (es) 2016-06-21 2021-10-28 X4 Pharmaceuticals Inc Inhibidores de CXCR4 y usos de los mismos
MX392743B (es) 2017-04-12 2025-03-12 Magenta Therapeutics Inc Antagonistas del receptor de hidrocarburo de arilo y sus usos.
WO2019089833A1 (en) 2017-10-31 2019-05-09 Magenta Therapeutics Inc. Compositions and methods for hematopoietic stem and progenitor cell transplant therapy
EP3704232A1 (en) 2017-10-31 2020-09-09 Magenta Therapeutics, Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells
CN111712262A (zh) 2017-12-06 2020-09-25 美真达治疗公司 用于动员造血干细胞和祖细胞的给药方案
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
EP3735412B1 (en) 2018-01-03 2024-02-21 EdiGene Biotechnology, Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders
US20210315909A1 (en) 2018-07-11 2021-10-14 Arrys Therapeutics, Inc. Polymorphic compounds and uses thereof
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
AU2019392904B9 (en) 2018-12-07 2022-12-22 University Of Maryland, Baltimore Non-ATP/catalytic site p38 mitogen activated protein kinase inhibitors
CN110787838B (zh) * 2019-10-09 2021-10-29 江苏医药职业学院 一种双核配合物及其制备方法和应用
US20220401481A1 (en) 2019-11-01 2022-12-22 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
CA3171250A1 (en) 2020-03-10 2021-09-16 E. Lynne KELLEY Methods for treating neutropenia
CA3176979A1 (en) 2020-04-27 2021-11-04 Anthony Boitano Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
US20230416239A1 (en) * 2020-11-12 2023-12-28 Conservatoire National des Arts et Métiers Compounds and methods for treating a cytokine-mediated disease
WO2022197776A1 (en) 2021-03-16 2022-09-22 Magenta Therapeutics, Inc. Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients
WO2022204046A1 (en) 2021-03-23 2022-09-29 Gen1E Lifesciences Inc. Substituted naphthyl p38alpha mitogen-activated protein kinase inhibitors
US12077546B2 (en) 2021-04-10 2024-09-03 Sumitomo Pharma Co., Ltd. Bicyclic pyridine derivative
MX2023011963A (es) * 2021-04-10 2023-10-19 Sumitomo Pharma Co Ltd Derivado biciclico de piridina.
CN117177977A (zh) * 2021-04-10 2023-12-05 住友制药株式会社 二环吡啶衍生物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7409399A (nl) * 1973-07-19 1975-01-21 Rhone Poulenc Sa Werkwijze ter bereiding van thermostabiele har- sen en voorwerpen geheel of gedeeltelijk be- staande uit deze harsen.
US5021409A (en) * 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
WO1991011994A1 (fr) * 1990-02-14 1991-08-22 Chugai Seiyaku Kabushiki Kaisha Inhibiteur de la formation de lipoproteines denaturees de faible densite
GB9126677D0 (en) * 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
GB9200245D0 (en) 1992-01-07 1992-02-26 British Bio Technology Compounds
GB9400411D0 (en) * 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
CA2189355A1 (en) * 1995-03-01 1996-09-06 Yasuo Onoda Imidazoquinazoline derivatives
GB9511357D0 (en) 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
AU4779897A (en) * 1996-10-02 1998-04-24 Novartis Ag Fused pyrazole derivatives and processes for their preparation
JP3060214B2 (ja) * 1997-04-10 2000-07-10 小野薬品工業株式会社 縮合ピペリジン化合物、その製造方法およびその化合物を有効成分とする薬剤
US5843146A (en) * 1997-04-30 1998-12-01 Medtronic Incorporated Adjustable medical lead anchor
WO1999004794A1 (en) * 1997-07-25 1999-02-04 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
US6172061B1 (en) 1997-12-19 2001-01-09 Takeda Chemical Industries, Ltd. Pharmaceutical composition for antagonizing CCR5 comprising anilide derivative
ATE292120T1 (de) * 1998-07-02 2005-04-15 Neurosearch As Kaliumkanal-blockierende mittel
ATE291423T1 (de) * 1998-08-20 2005-04-15 Agouron Pharma Nicht-peptidische gnrh agentia, verfahren und zwischenverbindungen zur ihren herstellung
BR0010655A (pt) * 1999-03-24 2002-02-13 Anormed Inc Compostos heterocìclicos para ligação ao receptor de quimiocina
US6750348B1 (en) * 1999-03-24 2004-06-15 Anormed, Inc. Chemokine receptor binding heterocyclic compounds

Also Published As

Publication number Publication date
US7629337B2 (en) 2009-12-08
CN1351601A (zh) 2002-05-29
WO2000056729A1 (en) 2000-09-28
NO323703B1 (no) 2007-06-25
EP1163238B1 (en) 2006-05-31
EP1163238A1 (en) 2001-12-19
KR20010108393A (ko) 2001-12-07
NO20014593D0 (no) 2001-09-21
DE60028354D1 (de) 2006-07-06
HK1043985A1 (en) 2002-10-04
AP1654A (en) 2006-09-01
KR100766289B1 (ko) 2007-10-11
US20060264434A1 (en) 2006-11-23
AP2001002269A0 (en) 2001-09-30
NO20014593L (no) 2001-10-29
CZ20013421A3 (cs) 2002-03-13
DE60028354T2 (de) 2007-02-08
CA2368047A1 (en) 2000-09-28
ES2265923T3 (es) 2007-03-01
AU3546000A (en) 2000-10-09
NZ514709A (en) 2003-03-28
HUP0200761A3 (en) 2003-05-28
ATE327988T1 (de) 2006-06-15
MXPA01009674A (es) 2003-07-21
HUP0200761A2 (en) 2002-06-29
US20100105915A1 (en) 2010-04-29
HK1043985B (en) 2006-11-24
PL350998A1 (en) 2003-02-24
AU775123B2 (en) 2004-07-15
CN1219780C (zh) 2005-09-21
IL145401A (en) 2007-07-24
TR200102799T2 (tr) 2002-07-22
JP2003524620A (ja) 2003-08-19
IL145401A0 (en) 2002-06-30

Similar Documents

Publication Publication Date Title
BR0010655A (pt) Compostos heterocìclicos para ligação ao receptor de quimiocina
BR0111230A (pt) Composto, e, uso e processo para a preparação do mesmo
BR9814340A (pt) Derivados de indol como inibidores de fator xa
CO5570660A2 (es) Indazolilpirrolotriazinas c-6 modificadas
FI102068B1 (fi) Menetelmä ja välituote farmakologisesti vaikuttavien bentsimidatsolijohdannaisten valmistamiseksi
KR890000470A (ko) 2,2-디메틸크로만-3-올 유도체, 그의 제조방법 및 그를 함유하는 약학 조성물
BRPI0406721A (pt) Compostos condensados de furano
GB1461209A (en) Thienyl and thietyl compounds
KR920012082A (ko) Ace 억제제로서 유용한 신규 아미노 및 니트로 함유 삼환식 화합물
KR890014098A (ko) 카테콜 아민 유도체를 함유하여 이루어지는 중추성 신경퇴행성 질환의 진행방지 및 치료제
BRPI0518533A2 (pt) 18-metil-19-nor-pregn-4-en-21,17- carbolactona, bem como preparados farmacÊuticos contendo as mesmas
BR0012032A (pt) Derivado do grupo a de estreptograminas, processo de preparação do mesmo, e composição farmacêutica
BR0016953A (pt) Derivados de 4-fenil-1-piperazinila, -piperidinila e tetraidropiridila substituìdo por halogênio, composto, composição farmacêutica, uso e método de tratamento
KR900016098A (ko) 카페인산의 유도체 및 이를 함유하는 약제학적 조성물
ATE66674T1 (de) Dihydropyridin-derivate, verfahren zu ihrer herstellung, diese enthaltende pharmazeutische zusammensetzungen, und verfahren zur herstellung dieser zusammensetzungen.
ES2073258T3 (es) Nuevos derivados de la urea, su preparacion y su aplicacion en terapeutica.
CA2289787A1 (en) Fungicidal mixtures
KR860008973A (ko) 2-피롤리돈 유도체
DE3851856D1 (de) 1,4-Dihydropyridin-Derivate und diese enthaltende pharmazeutische Zusammensetzungen.
BR0017023A (pt) Derivados amino substituìdos ramificados do 3-amino-1-fenil-1h [1,2,4] triazol, processos para o respectivo preparo e composições farmacêuticas que os contêm
ES2004141A6 (es) Un procedimiento de preparacion de nuevas 1,4-dihidropiridinas
KR880007462A (ko) 빈뇨치료용 프로피오페논 유도체
EA200000389A2 (ru) Новые замещенные пиридины или пиперидины, способ их получения и содержащие их фармацевтические композиции
ATE23995T1 (de) Pyridin-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
KR900016178A (ko) 2-치환 n,n&#39;-디트리메톡시벤조일 피페라진, 그의 제조 방법 및 그를 함유하는 치료 조성물

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements